Abstract:

Abstract: Diabetic kidney disease is currently the most common cause of end stage renal disease, not only in the Western countries but also in the developing nations. While the available therapeutic options remain not very effective, there is a strong ongoing effort to understand the pathogenesis better and develop more useful biomarkers. As the pathogenic mediators and signaling pathways get better defined, the scope of novel pharmaceutical agents to address such mediating factors as therapeutic targets is advancing. The efficiency of these new management strategies for diabetic kidney disease is promising in animal models and some small clinical trials. This review provides, in addition to a brief synopsis of currently used strategies, a comprehensive review of potential therapies that have been evolving in the past decade with a specific focus on the promising agents.

Key words: diabetic kidney disease, drugs , progress